Get the Stockscreener App
0.7126
1.27%
-0.0092
Nautilus Biotechnology Inc stock is traded at $0.7126, with a volume of 153.60K.
It is down -1.27% in the last 24 hours and down -1.03% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$0.7218
Open:
$0.739
24h Volume:
153.60K
Relative Volume:
0.51
Market Cap:
$90.01M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-1.2725
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
-2.52%
1M Performance:
-1.03%
6M Performance:
-58.33%
1Y Performance:
-69.15%
1-Day Range:
$0.71
$0.74
1-Week Range:
$0.71
$0.7628
52-Week Range:
$0.66
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.7126 | 91.17M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
Is Nautilus Biotechnology Inc. stock poised for growthJuly 2025 Setups & Trade Opportunity Analysis Reports - Newser
Combining price and volume data for Nautilus Biotechnology Inc.2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Can swing trading help recover from Nautilus Biotechnology Inc. lossesJuly 2025 Review & AI Enhanced Trade Execution Alerts - Newser
Visual trend scoring systems applied to Nautilus Biotechnology Inc.Weekly Profit Analysis & Technical Confirmation Alerts - Newser
Quantitative breakdown of Nautilus Biotechnology Inc. recent moveWeekly Trading Summary & Community Driven Trade Alerts - Newser
Detecting support and resistance levels for Nautilus Biotechnology Inc.2025 Top Decliners & Safe Capital Growth Trade Ideas - Newser
Tools to monitor Nautilus Biotechnology Inc. recovery probabilityShare Buyback & Safe Entry Point Alerts - Newser
What makes Nautilus Biotechnology Inc. stock price move sharply2025 Major Catalysts & Community Verified Swing Trade Signals - Newser
Using Python tools to backtest Nautilus Biotechnology Inc. strategiesJuly 2025 Update & High Yield Stock Recommendations - Newser
Will Nautilus Biotechnology Inc. stock go up soonAnalyst Upgrade & Smart Allocation Stock Tips - Newser
Why Nautilus Biotechnology Inc. stock attracts strong analyst attentionEarnings Risk Report & Weekly Stock Performance Updates - sundaytimes.kr
What Fibonacci levels say about Nautilus Biotechnology Inc. reboundWeekly Investment Recap & Advanced Technical Signal Analysis - Newser
Heatmap analysis for Nautilus Biotechnology Inc. and competitorsTrade Volume Report & Fast Momentum Stock Entry Tips - Newser
How to integrate Nautilus Biotechnology Inc. into portfolio analysis toolsAI Entry Timing Prediction for Swing Traders - Newser
Can trapped investors hope for a rebound in Nautilus Biotechnology Inc.Breakout Watcher with Entry and Exit Alerts - Newser
Using R and stats models for Nautilus Biotechnology Inc. forecastingStrategy Playbook for Risk Controlled Trades - Newser
Using data filters to optimize entry into Nautilus Biotechnology Inc.Portfolio Allocation Strategy for Stability - Newser
Momentum divergence signals in Nautilus Biotechnology Inc. chartReal Market Tracker with Price Action Tools - Newser
Pattern recognition hints at Nautilus Biotechnology Inc. upsideSwing Trade Watchlist with Entry Zones - Newser
What earnings revisions data tells us about Nautilus Biotechnology Inc.Retirement Investment Outlook and Return Summary - Newser
How Nautilus Biotechnology Inc. stock performs during market volatilityLong-Term Growth Trend Summary With Confidence - Newser
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nautilus Biotechnology Inc Stock (NAUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mallick Parag | Chief Scientist |
May 08 '25 |
Buy |
0.73 |
12,000 |
8,788 |
20,491,892 |
| Mallick Parag | Chief Scientist |
May 12 '25 |
Buy |
0.73 |
1,500 |
1,098 |
20,493,392 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 19 '25 |
Buy |
0.99 |
53,300 |
53,028 |
10,117,788 |
| Patel Sujal M | CEO, President, and Secretary |
Mar 20 '25 |
Buy |
1.00 |
23,933 |
23,890 |
10,141,721 |
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):